Ming-Chung Wang

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Chiun Hsu, Chao A. Hsiung, Ih‐Jen Su et al. · Hepatology · 2008 · 305 citations · Full text

Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study

Chiun Hsu, Hsiao‐Hui Tsou, Shyh-Jer Lin et al. · Hepatology · 2013 · 271 citations · Full text

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

Hui‐Jen Tsai, Shih Sheng Jiang, Wen-Chun Hung et al. · Scientific Reports · 2017 · 70 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Phase Ii Study +19

Emerging kinetics of BCR–ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure

Lee‐Yung Shih, Ming‐Chung Kuo, Ching-Yuan Kuo et al. · Leukemia Research · 2012 · 17 citations

Hematological Malignancy, Tumor Biology, Systems Biology +12